Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Twice-daily Dosing 4-AP on Functional Recovery After Spinal Cord Injury
NCT06853015Phase 2Recruiting
- Sponsor
- Shirley Ryan AbilityLab
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalfampridine in spinal cord injury (SCI), sponsored by Shirley Ryan AbilityLab. Started Feb 2025; status: recruiting.
02
Drugs
dalfampridine
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT06853015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853015.